[Simultaneous combined radio-/chemotherapy of locally recurring breast cancer].
Combined simultaneous radiochemotherapy is our treatment conception for the locoregionally recurrent mammary carcinoma. With this therapy, complete or partial remissions are achieved in 92%. In only 25%, another recurrence appears within the irradiated region. The median survival time is 23 months. The results of the chemotherapy combination CMFV are better than the results of other combinations. Due to the good local effect, the quality of life without tumor of the thoracic wall is improved.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage
D003037:Cobalt Radioisotopes; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate
Simultane kombinierte Radio-/Chemotherapie des lokal rezidivierenden Mammakarzinoms.